ERYP - ERYTECH starts patient enrollment in cancer study

ERYTECH Pharma (ERYP) has announced that the first patient was enrolled in an early-stage investigator-sponsored trial for its lead asset Eryaspase in first-line pancreatic cancer.The single-arm, multi-center, open-label Phase 1 trial, initiated and sponsored by Georgetown University, Washington DC, USA, will enroll 18 patients who have received no prior chemotherapy for the treatment of locally advanced or metastatic pancreatic cancer.The study will escalate and add the dose of eryaspase to modified FOLFIRINOX to assess the safety and tolerability of the combination. From 4 possible dose levels of Eryaspase, it will determine the maximum tolerated dose in combination with mFOLFIRINOX.FOLFIRINOX is a commonly used first-line chemotherapy regimen for the treatment of pancreatic cancer. The trial will attempt to demonstrate the addition of eryaspase to mFOLFIRINOX will be safe and show preliminary signs of efficacy in patients with advanced pancreatic cancer.Of an estimated 185,000 new cases of pancreatic cancer diagnosed in Europe and

For further details see:

ERYTECH starts patient enrollment in cancer study